Is ABEO or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Aktis Oncology N/A N/A N/A

Does the media prefer ABEO or AKTS?

In the previous week, Abeona Therapeutics had 2 more articles in the media than Aktis Oncology. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.41 beat Abeona Therapeutics' score of 0.01 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABEO or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -34.89% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Oric Pharmaceuticals N/A -34.89% -32.98%

Does the media favor ABEO or ORIC?

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Oric Pharmaceuticals and 3 mentions for Abeona Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.33 beat Abeona Therapeutics' score of 0.01 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ABEO or ARDX?

In the previous week, Ardelyx had 3 more articles in the media than Abeona Therapeutics. MarketBeat recorded 6 mentions for Ardelyx and 3 mentions for Abeona Therapeutics. Ardelyx's average media sentiment score of 0.89 beat Abeona Therapeutics' score of 0.01 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVLN or ABEO more profitable?

Avalyn Pharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Abeona Therapeutics N/A -53.98% -38.52%

Does the media prefer AVLN or ABEO?

In the previous week, Abeona Therapeutics had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Abeona Therapeutics and 2 mentions for Avalyn Pharma. Abeona Therapeutics' average media sentiment score of 0.01 beat Avalyn Pharma's score of -0.50 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ABEO or IMTX?

In the previous week, Abeona Therapeutics and Abeona Therapeutics both had 3 articles in the media. Immatics' average media sentiment score of 0.70 beat Abeona Therapeutics' score of 0.01 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abeona Therapeutics (ABEO) Competitors

$6.82 +0.43 (+6.73%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$6.77 -0.05 (-0.73%)

As of 08:21 AM Eastern

Compare

ABEO vs. AKTS, ORIC, ARDX, AVLN, and IMTX

Should you buy Abeona Therapeutics stock or one of its competitors? MarketBeat compares Abeona Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abeona Therapeutics include Aktis Oncology (AKTS), Oric Pharmaceuticals (ORIC), Ardelyx (ARDX), Avalyn Pharma (AVLN), and Immatics (IMTX).

How does Abeona Therapeutics compare to Aktis Oncology?

Abeona Therapeutics (NASDAQ:ABEO) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Aktis Oncology	N/A	N/A	N/A

Abeona Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 178.59%. Aktis Oncology has a consensus target price of $34.60, indicating a potential upside of 51.49%. Given Abeona Therapeutics' higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Abeona Therapeutics had 2 more articles in the media than Aktis Oncology. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.41 beat Abeona Therapeutics' score of 0.01 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abeona Therapeutics has higher earnings, but lower revenue than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	66.78	$71.18M	$0.97	7.03
Aktis Oncology	$6.50M	187.64	-$63.73M	-$0.38	N/A

Summary

Aktis Oncology beats Abeona Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Abeona Therapeutics (NASDAQ:ABEO) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 178.59%. Oric Pharmaceuticals has a consensus price target of $19.27, indicating a potential upside of 43.08%. Given Abeona Therapeutics' higher probable upside, equities research analysts clearly believe Abeona Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oric Pharmaceuticals' return on equity of -34.89% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Oric Pharmaceuticals	N/A	-34.89%	-32.98%

Abeona Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Oric Pharmaceuticals and 3 mentions for Abeona Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.33 beat Abeona Therapeutics' score of 0.01 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	66.78	$71.18M	$0.97	7.03
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Summary

Abeona Therapeutics and Oric Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to Ardelyx?

Abeona Therapeutics (NASDAQ:ABEO) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abeona Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	66.78	$71.18M	$0.97	7.03
Ardelyx	$427.68M	2.89	-$61.60M	-$0.23	N/A

Abeona Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Ardelyx	-13.58%	-38.11%	-11.85%

Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 178.59%. Ardelyx has a consensus target price of $16.10, indicating a potential upside of 221.36%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Ardelyx had 3 more articles in the media than Abeona Therapeutics. MarketBeat recorded 6 mentions for Ardelyx and 3 mentions for Abeona Therapeutics. Ardelyx's average media sentiment score of 0.89 beat Abeona Therapeutics' score of 0.01 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ardelyx beats Abeona Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Abeona Therapeutics compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Avalyn Pharma presently has a consensus target price of $59.00, suggesting a potential upside of 91.99%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 178.59%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Abeona Therapeutics had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Abeona Therapeutics and 2 mentions for Avalyn Pharma. Abeona Therapeutics' average media sentiment score of 0.01 beat Avalyn Pharma's score of -0.50 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Abeona Therapeutics	$5.82M	66.78	$71.18M	$0.97	7.03

80.6% of Abeona Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avalyn Pharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Abeona Therapeutics beats Avalyn Pharma on 8 of the 12 factors compared between the two stocks.

How does Abeona Therapeutics compare to Immatics?

Abeona Therapeutics (NASDAQ:ABEO) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Abeona Therapeutics and Abeona Therapeutics both had 3 articles in the media. Immatics' average media sentiment score of 0.70 beat Abeona Therapeutics' score of 0.01 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 178.59%. Immatics has a consensus price target of $20.80, suggesting a potential upside of 121.75%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Abeona Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Immatics	-572.35%	-47.36%	-39.35%

Abeona Therapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	66.78	$71.18M	$0.97	7.03
Immatics	$54.60M	23.03	-$222.26M	-$1.99	N/A

Summary

Abeona Therapeutics beats Immatics on 10 of the 15 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$364.20M	$3.52B	$6.83B	$12.77B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	7.03	7.32	279.15	25.53
Price / Sales	66.78	1,279.23	591.00	92.31
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	2.32	17.25	13.02	6.11
Net Income	$71.18M	-$12.52M	$3.48B	$347.58M
7 Day Performance	9.47%	3.63%	3.39%	4.91%
1 Month Performance	6.56%	-5.38%	-2.80%	-2.06%
1 Year Performance	5.41%	49.44%	73.07%	21.03%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	3.4111 of 5 stars	$6.82 +6.7%	$19.00 +178.6%	+6.2%	$364.20M	$5.82M	7.03	90	Analyst Downgrade
AKTS Aktis Oncology	2.2585 of 5 stars	$24.21 +1.3%	$34.60 +42.9%	N/A	$1.28B	$6.50M	N/A	76	Upcoming Earnings
ORIC Oric Pharmaceuticals	2.3208 of 5 stars	$12.02 -0.7%	$19.27 +60.3%	+38.3%	$1.25B	N/A	N/A	80	News Coverage Earnings Report Upcoming Earnings Options Volume
ARDX Ardelyx	2.8564 of 5 stars	$5.06 +0.6%	$15.73 +210.8%	+14.1%	$1.24B	$407.32M	N/A	90	Upcoming Earnings
AVLN Avalyn Pharma	3.0001 of 5 stars	$27.62 -1.2%	$59.00 +113.6%	N/A	$1.22B	N/A	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. AKTS, ORIC, ARDX, AVLN, and IMTX

How does Abeona Therapeutics compare to Aktis Oncology?

Summary

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Abeona Therapeutics compare to Ardelyx?

Summary

How does Abeona Therapeutics compare to Avalyn Pharma?

Summary

How does Abeona Therapeutics compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. AKTS, ORIC, ARDX, AVLN, and IMTX

How does Abeona Therapeutics compare to Aktis Oncology?

Is ABEO or AKTS more profitable?

Do analysts recommend ABEO or AKTS?

Does the media prefer ABEO or AKTS?

Do institutionals & insiders hold more shares of ABEO or AKTS?

Which has higher valuation & earnings, ABEO or AKTS?

Summary

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Do analysts prefer ABEO or ORIC?

Do insiders & institutionals hold more shares of ABEO or ORIC?

Is ABEO or ORIC more profitable?

Which has more risk & volatility, ABEO or ORIC?

Does the media favor ABEO or ORIC?

Which has stronger earnings and valuation, ABEO or ORIC?

Summary

How does Abeona Therapeutics compare to Ardelyx?

Do insiders and institutionals hold more shares of ABEO or ARDX?

Which has better valuation and earnings, ABEO or ARDX?

Is ABEO or ARDX more profitable?

Which has more volatility & risk, ABEO or ARDX?

Do analysts prefer ABEO or ARDX?

Does the media favor ABEO or ARDX?

Summary

How does Abeona Therapeutics compare to Avalyn Pharma?

Do analysts prefer AVLN or ABEO?

Does the media prefer AVLN or ABEO?

Which has stronger valuation and earnings, AVLN or ABEO?

Do insiders & institutionals hold more shares of AVLN or ABEO?

Is AVLN or ABEO more profitable?

Summary

How does Abeona Therapeutics compare to Immatics?

Which has more volatility and risk, ABEO or IMTX?

Do insiders and institutionals have more ownership in ABEO or IMTX?

Does the media favor ABEO or IMTX?

Do analysts recommend ABEO or IMTX?

Is ABEO or IMTX more profitable?

Which has preferable earnings and valuation, ABEO or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools